Alnylam Pharmaceuticals Reports Third Quarter 2005 Financial Results; Company Continues Leadership with Products, Partnerships, Technology, and Intellectual Property for RNAi Therapeutics.

Extract

---

Alnylam Pharmaceuticals Reports Third Quarter 2005 Financial Results; Company Continues Leadership with Products, Partnerships, Technology, and Intellectual Property for RNAi Therapeutics.

CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the quarter ended September 30, 2005, and company highlights.

"Our progress over the last four months has propelled Alnylam significantly forward in our mission to build a leading product company founded on RNAi," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam Pharmaceuticals. "Pivotal recent events included the submission of our first IND for ALN-RSV01, our proprietary RNAi therapeutic for the treatment of RSV infection, and a major alliance forged with Novartis for the discovery, development, and commercialization of RNAi therapeutics. Significant success in this collaboration could lead to Alnylam receiving over $700 million in collective payments, not including royalties."

Cash, Cash Equivalents and Marketable Securities

At ...

See the full content of this document

---